Mobia Medical, Inc.

Filing Date

May 7, 2026

Transaction Date

May 7, 2026

Accession Number

0001734820-26-000007

Form Type

3

Footnotes

1. (F1)Each share of Series E-2 Preferred Stock and Series F Preferred Stock will convert into 0.287108814 shares of common stock immediately prior to the completion of the Issuer's initial public offering. The shares reported in Table II above are on an as-converted basis and have no expiration date.
2. (F2)These securities are held by U.S. Venture Partners XII, L.P. ("USVP XII").
3. (F3)Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and U.S. Venture Partners XII-A, L.P. ("USVP XII-A", and together with USVP XII, the "USVP XII Funds"). Presidio Management Group Select Fund I, L.L.C ("PMG SFI", and, together with USVP XII, USVP XII-A, U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"), and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. PMG XII and PMG SFI may be deemed to share voting and dispositive power over the stock held by USVP.
4. (F4)Jonathan D. Root, Richard W. Lewis, Dafina Toncheva and Steven M. Krausz are managing members of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by the USVP XII Funds. In addition, Casey M. Tansey is the managing partner and a managing member of PMG XII and PMG SFI, respectively, and may be deemed to share voting and dispositive power over the reported securities held by USVP. Each such persons and entities disclaim beneficial ownership of the reported securities held by USVP, except to the extent of any pecuniary interest therein.
5. (F5)These securities are held by USVP XII-A.
6. (F6)These securities are held by USVP SFI, on its own behalf and as nominee for USVP SFI-A.
7. (F7)The Convertible Notes will automatically convert into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
8. (F8)Convertible Notes held by USVP SFI, on its own behalf and as nominee for USVP SFI-A.